These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
691 related articles for article (PubMed ID: 22372628)
21. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Delanty N; Jones J; Tonner F Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371 [TBL] [Abstract][Full Text] [Related]
22. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083 [TBL] [Abstract][Full Text] [Related]
23. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838 [TBL] [Abstract][Full Text] [Related]
24. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial. Inoue Y; Liao W; Wang X; Du X; Tennigkeit F; Sasamoto H; Osakabe T; Hoshii N; Yuen N; Hong Z Epilepsy Res; 2021 Oct; 176():106705. PubMed ID: 34246118 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Grosso S; Parisi P; Spalice A; Verrotti A; Balestri P Eur J Paediatr Neurol; 2014 Jan; 18(1):55-9. PubMed ID: 24129195 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001 [TBL] [Abstract][Full Text] [Related]
31. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial. Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S; Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101 [TBL] [Abstract][Full Text] [Related]
32. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Harris JA; Murphy JA Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Zadeh WW; Escartin A; Byrnes W; Tennigkeit F; Borghs S; Li T; Dedeken P; De Backer M; Seizure; 2015 Sep; 31():72-9. PubMed ID: 26362380 [TBL] [Abstract][Full Text] [Related]
35. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Wechsler RT; Li G; French J; O'Brien TJ; D'Cruz O; Williams P; Goodson R; Brock M; Epilepsia; 2014 Jul; 55(7):1088-98. PubMed ID: 24915838 [TBL] [Abstract][Full Text] [Related]
36. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701 [TBL] [Abstract][Full Text] [Related]
37. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333 [TBL] [Abstract][Full Text] [Related]
38. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]
39. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Gidal BE; Ferry J; Majid O; Hussein Z Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853 [TBL] [Abstract][Full Text] [Related]
40. Minimizing pharmacodynamic interactions of high doses of lacosamide. Edwards HB; Cole AG; Griffiths AS; Lin B; Bean A; Krauss GL Acta Neurol Scand; 2012 Apr; 125(4):228-33. PubMed ID: 22070525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]